Komuro M, Maeda T, Kakuo H, Matsushita H, Shimada J
Pharmacokinetics Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
J Antimicrob Chemother. 1994 Oct;34(4):555-64. doi: 10.1093/jac/34.4.555.
A 1:4 by weight of combination of tazobactam, a new beta-lactamase inhibitor, and piperacillin, is now under development in Japan. After bolus iv administration of the combination to beagle dogs, piperacillin both significantly raised the area under plasma concentration time curve (AUC0 approximately infinity) and significantly decreased the total body clearance (Cltot) of tazobactam. The percentage binding of tazobactam and piperacillin to dog and human serum protein was the same for the combination as for the individual compounds. Piperacillin significantly decreased the renal clearance (Clr) and the clearance ratio (Cr) of tazobactam in dogs. Further, probenecid significantly decreased Clr of both tazobactam and piperacillin, and the Cr of tazobactam and piperacillin approximately reached unity. These results indicate that piperacillin inhibits the renal excretion of tazobactam. Both tazobactam and piperacillin are secreted by a tubular anion transport system which is identical to the probenecid secretion system.
新型β-内酰胺酶抑制剂他唑巴坦与哌拉西林按重量比1:4的组合目前正在日本进行研发。对小猎犬静脉注射该组合药物后,哌拉西林显著提高了他唑巴坦的血浆浓度-时间曲线下面积(AUC0至无穷大),并显著降低了他唑巴坦的总体清除率(Cltot)。他唑巴坦和哌拉西林与犬和人血清蛋白的结合百分比在组合药物与单独化合物中相同。哌拉西林显著降低了犬体内他唑巴坦的肾清除率(Clr)和清除率比值(Cr)。此外,丙磺舒显著降低了他唑巴坦和哌拉西林的Clr,且他唑巴坦和哌拉西林的Cr约达到1。这些结果表明哌拉西林抑制了他唑巴坦的肾排泄。他唑巴坦和哌拉西林均通过与丙磺舒分泌系统相同的肾小管阴离子转运系统分泌。